세계의 마이크로어레이 시장 예측(-2030년) : 제품, 유형, 용도, 최종 사용자 및 지역별 분석

According to Stratistics MRC, the Global Microarray Market is accounted for $4.70 billion in 2023 and is expected to reach $9.04 billion by 2030 growing at a CAGR of 9.8% during the forecast period. In genomics and molecular biology, microarrays are an effective technology that allow for the high-throughput, simultaneous investigation of many genes, proteins, or other substances. The market offers a broad variety of applications in research, diagnostics, and drug development and comprises many types of microarrays, including DNA, protein, and tissue microarrays. Custom microarrays are created by several organizations and researchers to meet their unique research requirements.

According to a research study published by the Royal Society of Chemistry in 2019, a portable fluorescence microarray imaging system that connects to a smartphone has been used for the detection of breast cancer gene expression.

Market Dynamics:

Driver:

Rise in the usage of microarrays in various applications

The market for microarrays has grown as a result of the growing use of microarrays in various applications. The need for microarray goods and services has increased as more scientists and organizations use them for clinical diagnostics, proteomics, genomics, and other areas. These days, microarrays are employed in many more fields, such as drug development, proteomics, clinical diagnostics, genomics, and environmental monitoring due to this diversity, the market is now more resilient to changes in certain industries and has been able to develop continuously. Drug development relies heavily on microarrays because they make target identification, toxicity assessment, and biomarker discovery easier.

Restraint:

Competition from next-generation sequencing (NGS)

Next-generation sequencing technologies can give complete molecular and genomic data; they have become more and more popular. They have so reduced microarrays' market share across a range of applications. Because of Next-generation sequencing breadth of information and high-throughput sequencing capabilities, researchers and physicians frequently use it. When considering technologies, it is frequently thought to be more potent and sophisticated than microarrays. This idea may discourage the use of microarrays in favour of next-generation sequencing in research and other settings, which might stunt the expansion of the microarray business.

Opportunity:

Growing awareness regarding personalized medicines

Molecular profiling of individual patients is the foundation of personalized medicine, which customizes medicinal interventions. In order to produce genetic and molecular data particular to each patient, microarrays are essential. The growing awareness among patients and healthcare professionals of the potential advantages of customized medicine has led to a surge in demand for these technologies. In the realm of customized medicine, interdisciplinary collaboration between researchers, healthcare practitioners, and biotechnology businesses is becoming more widespread.

Threat:

High maintenance

Microarray technology adoption may be hindered by the lack of qualified workers. If research organizations and clinical labs lack the staff with the necessary skills to properly run the technology, they can be reluctant to invest in microarray platforms. The analysis of microarray data might be challenging and call for bioinformatics knowledge. A shortage of qualified experts might lead to ineffective data processing, which would postpone research results, misunderstand them, and decrease scientific output thus hampering the market growth.

COVID-19 Impact

Through the investigation of host responses to the virus, patient gene expression alterations, and the creation of diagnostic tests, microarrays contributed to COVID-19 research. As a result, there was a rise in demand for virus-specific microarray-based tests. Thus, the pandemic caused changes in certain regions' objectives for financing research, with an emphasis on developing vaccines and researching infectious diseases. Furthermore, the market for microarrays may grow if more money is invested in life sciences research, like as proteomics and genomics, once the pandemic's acute phase has passed.

The protein microarrays segment is expected to be the largest during the forecast period

The protein microarrays segment is estimated to have a lucrative growth, as these proteomics research, protein microarrays are an effective and adaptable tool for examining the characteristics, relationships, and roles of proteins. Protein microarrays enable high-throughput analysis of the binding interactions of proteins and other molecules, much to DNA microarrays, which are used to examine gene expression. The advancement of protein microarray technology has produced increasingly sophisticated systems with improved sensitivity, specificity, and throughput.

The diseases diagnostics segment is expected to have the highest CAGR during the forecast period

The diseases diagnostics segment is anticipated to witness the highest CAGR growth during the forecast period, because the single nucleotide polymorphisms (SNPs) linked to genetic disorders, cancer, and infectious illnesses, as well as chromosomal abnormalities, are all found using these microarrays. These microarrays investigate protein-protein interactions, gene expression patterns, and protein localization in a variety of disorders using tissue slices or cultured cells. Moreover these diagnostic microarrays allow for customized treatment plans based on a patient's genetic or molecular profile in the age of personalized medicine thereby boosting the market growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the rising demand for cutting-edge healthcare solutions as well as enhanced genomics and personalized medicine research and development efforts are responsible for this expansion. The Asia Pacific area is home to several academic institutions, research labs, and biotechnology corporations that are actively involved in microarray research and development. This involves the creation of personalized microarrays for particular uses and the identification of biomarkers for a range of illnesses.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period; owing to one of the biggest and most developed markets for microarray technology. Particularly, the US is a significant centre for microarray creation and research. The North American microarray market is occupied by a number of multinational and local businesses that offer microarray platforms, reagents, and services. Agilent Technologies, Illumina, Thermo Fisher Scientific, PerkinElmer, and many more are some of the major companies in this sector are driving the market growth in this region.

Key players in the market

Some of the key players profiled in the Microarray Market include: Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., PerkinElmer, Inc., Bio-Rad Laboratories, GE Healthcare, Molecular Devices, LLC, Affymetrix, Merck & Co., Inc., Arrayit Corporation, Microarrays; Inc., NextGen Sciences, bioMerieux SA, RayBiotech Life, Inc, PathogenDx, Diasorin Group, Schott Minifab, Full Moon Biosystems.Inc and CapitalBio Technology Co, Ltd

Key Developments:

In October 2023, Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific™ Meridian™ EX System an electron-beam-based failure analysis solution designed to enable precise fault localization on advanced semiconductor logic technologies.

In October 2023, Thermo Fisher Scientific announced a companion diagnostic (CDx) partnership with Boehringer Ingelheim. Through this collaboration, the companies will work to develop CDx tests to help identify patients with non-small cell lung cancer (NSCLC) with specific genomic mutations.

In September 2023, Agilent Technologies Inc recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

Products Covered:

• Consumables
• Instruments
• Software & Services

Types Covered:

• Protein Microarrays
• DNA Microarrays
• Other Microarrays

Applications Covered:

• Drug Discovery
• Diseases Diagnostics
• Research Applications
• Agriculture
• Other Applications

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes
• Diagnostic Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Microarray Market, By Product

• 5.1 Introduction
• 5.2 Consumables
• 5.3 Instruments
• 5.4 Software & Services

6 Global Microarray Market, By Type

• 6.1 Introduction
• 6.2 Protein Microarrays
• 6.3 DNA Microarrays
• 6.4 Other Microarrays

7 Global Microarray Market, By Application

• 7.1 Introduction
• 7.2 Drug Discovery
• 7.3 Diseases Diagnostics
• 7.4 Research Applications
• 7.5 Agriculture
• 7.6 Other Applications

8 Global Microarray Market, By End User

• 8.1 Introduction
• 8.2 Pharmaceutical & Biotechnology Companies
• 8.3 Research & Academic Institutes
• 8.4 Diagnostic Laboratories
• 8.5 Other End Users

9 Global Microarray Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Agilent Technologies, Inc.
• 11.2 Thermo Fisher Scientific, Inc.
• 11.3 Illumina, Inc.
• 11.4 PerkinElmer, Inc.
• 11.5 Bio-Rad Laboratories
• 11.6 GE Healthcare
• 11.7 Molecular Devices, LLC
• 11.8 Affymetrix
• 11.9 Merck & Co., Inc.
• 11.10 Arrayit Corporation
• 11.11 Microarrays; Inc.
• 11.12 NextGen Sciences
• 11.13 bioMerieux SA
• 11.14 RayBiotech Life, Inc
• 11.15 PathogenDx
• 11.16 Diasorin Group
• 11.17 Schott Minifab
• 11.18 Full Moon Biosystems.Inc
• 11.19 CapitalBio Technology Co, Ltd